drugset / Trial / NCT07842523
Obinutuzumab in Systemic Sclerosis
Phase 2
Not yet recruiting
120 enrolled
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine if obinutuzumab is effective in systemic sclerosis
Timeline
- Start
- 2026-11
- Primary completion
- 2029-12
- Completion
- 2030-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |